Specify a stock or a cryptocurrency in the search bar to get a summary
Bio Path Holdings Inc
BPTHBio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing Liposomal Bcl-2 (BP1002) for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; Liposomal STAT3 (BP1003) for the treatment of pancreatic cancer, non-small cell lung cancer, and AML; and BP1001-A for the treatment of solid tumors. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Address: 4710 Bellaire Boulevard, Bellaire, TX, United States, 77401
Analytics
WallStreet Target Price
12 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures BPTH
Dividend Analytics BPTH
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History BPTH
Stock Valuation BPTH
Financials BPTH
Results | 2019 | Dynamics |